EP3359162A4 - Methods of treating injuries or conditions related to cns edema - Google Patents

Methods of treating injuries or conditions related to cns edema Download PDF

Info

Publication number
EP3359162A4
EP3359162A4 EP16854422.9A EP16854422A EP3359162A4 EP 3359162 A4 EP3359162 A4 EP 3359162A4 EP 16854422 A EP16854422 A EP 16854422A EP 3359162 A4 EP3359162 A4 EP 3359162A4
Authority
EP
European Patent Office
Prior art keywords
methods
conditions related
treating injuries
cns edema
edema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16854422.9A
Other languages
German (de)
French (fr)
Other versions
EP3359162A1 (en
EP3359162B1 (en
Inventor
Sven Martin Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Chesapeake LLC
Original Assignee
Biogen Chesapeake LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake LLC filed Critical Biogen Chesapeake LLC
Publication of EP3359162A1 publication Critical patent/EP3359162A1/en
Publication of EP3359162A4 publication Critical patent/EP3359162A4/en
Application granted granted Critical
Publication of EP3359162B1 publication Critical patent/EP3359162B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16854422.9A 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema Active EP3359162B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (3)

Publication Number Publication Date
EP3359162A1 EP3359162A1 (en) 2018-08-15
EP3359162A4 true EP3359162A4 (en) 2019-08-28
EP3359162B1 EP3359162B1 (en) 2022-12-21

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16854422.9A Active EP3359162B1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Country Status (15)

Country Link
US (2) US20180280325A1 (en)
EP (1) EP3359162B1 (en)
JP (3) JP7349786B2 (en)
KR (1) KR20180063296A (en)
CN (2) CN108348534A (en)
AU (2) AU2016335767B2 (en)
BR (1) BR112018006925A2 (en)
CA (1) CA3001321A1 (en)
EA (1) EA201890893A1 (en)
ES (1) ES2940669T3 (en)
HK (1) HK1257542A1 (en)
IL (1) IL258509B2 (en)
MA (1) MA45574A (en)
MX (1) MX2018004286A (en)
WO (1) WO2017062765A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2846787B1 (en) 2012-05-08 2018-08-29 Aeromics, Inc. Compounds for use in the treatment of aquaporin-mediated diseases
US9949991B2 (en) 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
JP2022531312A (en) * 2019-05-02 2022-07-06 バイオジェン チェサピーク エルエルシー Treatment of subjects suffering from central nervous system contusion
US20230348371A1 (en) * 2020-07-17 2023-11-02 Shanghai Senhui Medicine Co., Ltd. Sulfonylurea derivative and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DK1529058T3 (en) * 2002-03-20 2013-12-02 Us Of America As Represented By The Dept Of Veterans Affairs NON-SELECTIVE CATION CHANNEL IN NERV CELLS AND SUR1 ANTAGONISTS FOR TREATMENT OF CORE SWORD
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
EP2224913B1 (en) * 2007-12-04 2014-10-15 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
CA3225438A1 (en) * 2010-07-19 2012-01-26 Remedy Pharmaceuticals, Inc. Methods of intravenous adminstration of glyburide and other drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KURLAND DAVID B; TOSUN CIGDEM; PAMPORI ADAM; KARIMY JASON K; CAFFES NICHOLAS M; GERZANICH VOLODYMYR; SIMARD J MARC: "Glibenclamide for the treatment of acute CNS injury.", PHARMACEUTICALS, vol. 6, 1 October 2013 (2013-10-01) - 11 October 2013 (2013-10-11), pages 1287 - 1303, XP002790226 *
SHETH ET AL: "Exploratory analysis of glyburide as a novel therapy for preventing brain swelling.", NEUROCRIT. CARE, vol. 21, no. 1, 18 May 2015 (2015-05-18) - 19 May 2015 (2015-05-19), pages 43 - 51, XP002790225 *

Also Published As

Publication number Publication date
IL258509A (en) 2018-05-31
CN108348534A (en) 2018-07-31
ES2940669T3 (en) 2023-05-10
KR20180063296A (en) 2018-06-11
AU2016335767A1 (en) 2018-05-24
AU2022279369A1 (en) 2023-01-19
US11951085B2 (en) 2024-04-09
CA3001321A1 (en) 2017-04-13
JP2021073317A (en) 2021-05-13
US20180280325A1 (en) 2018-10-04
JP2018530564A (en) 2018-10-18
IL258509B2 (en) 2023-04-01
JP7349786B2 (en) 2023-09-25
HK1257542A1 (en) 2019-10-25
EA201890893A1 (en) 2018-09-28
MX2018004286A (en) 2018-08-09
JP2023053274A (en) 2023-04-12
BR112018006925A2 (en) 2018-10-16
MA45574A (en) 2019-05-15
WO2017062765A1 (en) 2017-04-13
CN115737816A (en) 2023-03-07
AU2016335767A8 (en) 2018-06-28
US20220125750A1 (en) 2022-04-28
EP3359162A1 (en) 2018-08-15
AU2016335767B2 (en) 2022-10-06
IL258509B (en) 2022-12-01
EP3359162B1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
IL286888A (en) Use of pridopidine to treat depression or anxiety
HK1259453A1 (en) Compounds and compositions useful for treating disorders related to ntrk
HK1255330A1 (en) Compounds and compositions useful for treating disorders related to ntrk
IL285151B1 (en) Methods of treating fgf21-associated disorders
IL266770A (en) Methods of treating inflammatory conditions
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
IL253197A0 (en) Methods of treating conditions related to the s1p1 receptor
IL285003A (en) Treatment of joint conditions
IL253118A0 (en) Methods of treating inflammatory diseases
HK1257542A1 (en) Methods of treating injuries or conditions related to cns edema
SG11201702688UA (en) Methods of treating rsv infections
HK1252037A1 (en) Methods of treating inflammatory diseases
HK1247789A1 (en) Compositions and methods for treatment of edema
HK1247818A1 (en) Method of treating diseases
ZA201903408B (en) Process for purification of pyrazolpyridazines
EP3182992A4 (en) Methods of treating mild brain injury
IL255498A (en) Treatment of pruritus
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
HK1246679A1 (en) Treatment of filarial diseases
HK1243937A1 (en) Methods of treating diseases
EP3215178A4 (en) Treatment of cns inflammatory disorders
PL3154993T3 (en) Process for the purification of l-alpha-glycerophosphorylcholine
DK3350071T3 (en) Improvements relating to drainage of material
SG10201601829QA (en) Improvements relating to drainage of material
AU2015901877A0 (en) Treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/64 20060101AFI20190409BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190729

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/64 20060101AFI20190723BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200930

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602016077055

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031640000

Ipc: A61P0025280000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/451 20060101ALI20220607BHEP

Ipc: A61K 31/18 20060101ALI20220607BHEP

Ipc: A61P 9/10 20060101ALI20220607BHEP

Ipc: A61P 25/28 20060101AFI20220607BHEP

INTG Intention to grant announced

Effective date: 20220711

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016077055

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1538695

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20221221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230321

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2940669

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20230510

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1538695

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230421

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230421

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016077055

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

26N No opposition filed

Effective date: 20230922

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231206

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231228

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231219

Year of fee payment: 8

Ref country code: FR

Payment date: 20231219

Year of fee payment: 8

Ref country code: DE

Payment date: 20231219

Year of fee payment: 8

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20240502 AND 20240508